Cargando…

Syndecan-1 (CD138) Modulates Triple-Negative Breast Cancer Stem Cell Properties via Regulation of LRP-6 and IL-6-Mediated STAT3 Signaling

Syndecan-1 (CD138), a heparan sulfate proteoglycan, acts as a coreceptor for growth factors and chemokines and is a molecular marker associated with epithelial-mesenchymal transition during development and carcinogenesis. Resistance of Syndecan-1-deficient mice to experimentally-induced tumorigenesi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ibrahim, Sherif A., Hassan, Hebatallah, Vilardo, Laura, Kumar, Sampath Katakam, Kumar, Archana Vijaya, Kelsch, Reinhard, Schneider, Cornelia, Kiesel, Ludwig, Eich, Hans Theodor, Zucchi, Ileana, Reinbold, Rolland, Greve, Burkhard, Götte, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3877388/ https://www.ncbi.nlm.nih.gov/pubmed/24392029 http://dx.doi.org/10.1371/journal.pone.0085737

Ejemplares similares

Syndecan-1-Dependent Regulation of Heparanase Affects Invasiveness, Stem Cell Properties, and Therapeutic Resistance of Caco2 Colon Cancer Cells
por: Katakam, Sampath Kumar, et al.
Publicado: (2020)

The Heparan Sulfate Sulfotransferases HS2ST1 and HS3ST2 Are Novel Regulators of Breast Cancer Stem-Cell Properties
por: Teixeira, Felipe C. O. B., et al.
Publicado: (2020)

An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ
por: Götte, Martin, et al.
Publicado: (2007)

The Cell Surface Heparan Sulfate Proteoglycan Syndecan-3 Promotes Ovarian Cancer Pathogenesis
por: Hillemeyer, Lara, et al.
Publicado: (2022)

Syndecan-1 Promotes Angiogenesis in Triple-Negative Breast Cancer through the Prognostically Relevant Tissue Factor Pathway and Additional Angiogenic Routes
por: Nassar, Eyyad, et al.
Publicado: (2021)

Identification of functionally related genes using data mining and data integration: a breast cancer case study
por: Mosca, Ettore, et al.
Publicado: (2009)

Differential Impact of Membrane-Bound and Soluble Forms of the Prognostic Marker Syndecan-1 on the Invasiveness, Migration, Apoptosis, and Proliferation of Cervical Cancer Cells
por: Hilgers, Katharina, et al.
Publicado: (2022)

Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways
por: Ibrahim, Sherif Abdelaziz, et al.
Publicado: (2017)

Syndecan-1 (CD138), Carcinomas and EMT
por: Couchman, John R.
Publicado: (2021)

The immunomodulatory role of tumor Syndecan-1 (CD138) on ex vivo tumor microenvironmental CD4(+) T cell polarization in inflammatory and non-inflammatory breast cancer patients
por: Saleh, Moshira Ezzat, et al.
Publicado: (2019)

Utility of CD138/syndecan-1 immunohistochemistry for localization of plasmacytes is tissue-dependent in B6 mice
por: Meyerholz, David K., et al.
Publicado: (2022)

Tumor suppressor miR-218 directly targets epidermal growth factor receptor (EGFR) expression in triple-negative breast cancer, sensitizing cells to irradiation
por: Wischmann, Franz-Josef, et al.
Publicado: (2023)

A rat mammary gland cancer cell with stem cell properties of self-renewal and multi-lineage differentiation
por: Cocola, Cinzia, et al.
Publicado: (2008)

Dual Knockdown of Musashi RNA-Binding Proteins MSI-1 and MSI-2 Attenuates Putative Cancer Stem Cell Characteristics and Therapy Resistance in Ovarian Cancer Cells
por: Löblein, Maria T., et al.
Publicado: (2021)

HS2ST1‐dependent signaling pathways determine breast cancer cell viability, matrix interactions, and invasive behavior
por: Vijaya Kumar, Archana, et al.
Publicado: (2020)

A Versatile Tool for Stable Inhibition of microRNA Activity
por: Pelucchi, Paride, et al.
Publicado: (2013)

The Heparan Sulfate Proteoglycan Syndecan-1 Triggers Breast Cancer Cell-Induced Coagulability by Induced Expression of Tissue Factor
por: Hassan, Nourhan, et al.
Publicado: (2023)

The Intensity and Pattern of Syndecan-1 (CD138) Expression in Normal and Diseased Livers
por: Atique, Muhammad, et al.
Publicado: (2023)

Knockdown of the prognostic cancer stem cell marker Musashi-1 decreases radio-resistance while enhancing apoptosis in hormone receptor-positive breast cancer cells via p21(WAF1/CIP1)
por: Troschel, Fabian M., et al.
Publicado: (2021)

LRP5 and LRP6 in Wnt Signaling: Similarity and Divergence
por: Ren, Qian, et al.
Publicado: (2021)

Syndecan-1 as a Regulator of Chemokine Function
por: Götte, Martin, et al.
Publicado: (2003)

Syndecan-1 (sCD138) levels in chronic lymphocytic leukemia: clinical and hematological correlations
por: Sharma, Monica, et al.
Publicado: (2018)

Prevalence of Syndecan-1 (CD138) Expression in Different Kinds of Human Tumors and Normal Tissues
por: Kind, Simon, et al.
Publicado: (2019)

Oxidized phospholipids are ligands for LRP6
por: Wang, Lei, et al.
Publicado: (2018)

Cholesterol-induced LRP3 downregulation promotes cartilage degeneration in osteoarthritis by targeting Syndecan-4
por: Cao, Chenxi, et al.
Publicado: (2022)

Dissecting Molecular Differences between Wnt Coreceptors LRP5 and LRP6
por: MacDonald, Bryan T., et al.
Publicado: (2011)

Role of Syndecans in Ovarian Cancer: New Diagnostic and Prognostic Biomarkers and Potential Therapeutic Targets
por: Oto, Julia, et al.
Publicado: (2023)

Soluble syndecan-1 (CD138): is it useful as a prognostic factor in Korean patients with multiple myeloma?
por: Lee, Je-Jung
Publicado: (2010)

Disease Stage-Specific Pathogenicity of CD138 (Syndecan 1)-Expressing T Cells in Systemic Lupus Erythematosus
por: Liu, Lunhua, et al.
Publicado: (2020)

Where Wnts Went: The Exploding Field of Lrp5 and Lrp6 Signaling in Bone
por: Williams, Bart O, et al.
Publicado: (2009)

Knockdown of the stem cell marker Musashi-1 inhibits endometrial cancer growth and sensitizes cells to radiation
por: Falke, Isabel, et al.
Publicado: (2022)

Transmembrane Protein TMEM230, a Target of Glioblastoma Therapy
por: Cocola, Cinzia, et al.
Publicado: (2021)

Dkk1 Stabilizes Wnt Co-Receptor LRP6: Implication for Wnt Ligand-Induced LRP6 Down-Regulation
por: Li, Yonghe, et al.
Publicado: (2010)

Lrp5 and Lrp6 Exert Overlapping Functions in Osteoblasts during Postnatal Bone Acquisition
por: Riddle, Ryan C., et al.
Publicado: (2013)

Relationship between circulating syndecan-1 levels (CD138s) and serum free light chains in monoclonal gammopathies
por: Cigliana, Giovanni, et al.
Publicado: (2015)

Syndecan-4 as a Pathogenesis Factor and Therapeutic Target in Cancer
por: Onyeisi, Jessica Oyie Sousa, et al.
Publicado: (2021)

LRP5 and LRP6 Are Not Required for Protective Antigen–Mediated Internalization or Lethality of Anthrax Lethal Toxin
por: Young, John J, et al.
Publicado: (2007)

Knockdown of Musashi RNA Binding Proteins Decreases Radioresistance but Enhances Cell Motility and Invasion in Triple-Negative Breast Cancer
por: Troschel, Fabian M., et al.
Publicado: (2020)

Syndecan-1 Depletion Has a Differential Impact on Hyaluronic Acid Metabolism and Tumor Cell Behavior in Luminal and Triple-Negative Breast Cancer Cells
por: Valla, Sofía, et al.
Publicado: (2021)

Characterization and dynamics of the soluble immunological microenvironment in melanoma patients undergoing radiotherapy
por: Oertel, Michael, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fpim2di1gkgoiksc17gqk4f7re